ico_admin

iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo

ico_admin2021-05-11T23:04:37+00:00May 10th, 2021|2021, Press Releases|

ico_admin2021-05-03T19:54:13+00:00May 1st, 2021|2021, Press Releases|

Press Release For Immediate Release NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION

ico_admin2021-04-28T01:28:34+00:00April 28th, 2021|2021, Press Releases|

ico_admin2021-04-23T07:16:59+00:00April 23rd, 2021|2021, Press Releases|

ico_admin2021-03-22T17:00:01+00:00March 22nd, 2021|2021, Press Releases|

March 15, 2021, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or

ico_admin2021-03-16T00:37:52+00:00March 15th, 2021|2021, Press Releases|

March 11, 2021, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or

ico_admin2021-03-12T01:01:51+00:00March 11th, 2021|2021, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:

ico_admin2021-02-18T21:53:35+00:00January 11th, 2021|2021, Press Releases|

ico_admin2021-02-21T21:40:18+00:00January 1st, 2021|2021, Presentations|

ico_admin2021-02-21T21:40:49+00:00January 1st, 2021|2020, Presentations|